| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M13602 | Abemaciclib metabolite M18 hydrochloride | Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. |
| M13599 | CCT-251921 | CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. |
| M13597 | BI-1347 | BI-1347 is a potent CDK8 inhibitor extracted from patent WO2017202719A1, product I-003, has an IC50 of 1.1 nM. |
| M13594 | Alsterpaullone | Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. |
| M13424 | CTX-712 | Ctx-712 is a firsit-in-class, oral, highly selective small-molecule inhibitor targeting CDC2-like kinase (CLK). |
| M11018 | Cirtuvivint | Cirtuvivint (SM08502) is a potent orally active CDC-like kinase (CLK) inhibitor that can be used in the study of solid tumors. |
| M10913 | THZ1-R | THZ1-R is a non-cysteine-reactive analogue of THZ1 with reduced activity against CDK7 inhibition. THZ1-R in combination with CDK7 Kd 142 nM. |
| M10886 | Samuraciclib hydrochloride | Samuraciclib (ICEC0942, CT7001) is a novel oral CDK7 inhibitor with an IC50 of 40 nM. It has IC50 values for other CDK proteins such as CDK1, CDK2, CDK5 and CDK9 as 45, 15, 230 and 30 times higher than that of CDK7 IC50, respectively. ICEC0942 (CT7001) promotes cell cycle blocking and apoptosis. |
| M10879 | RGB-286638 | RGB-286638 is a potent CDK inhibitor that inhibits cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 activity,IC50 1, 2, 3, 4, 5 and 5 nM, respectively, and can inhibit GSK-3β, TAK1, Jak2 and MEK1.IC50 The values are 3, 5, 50, and 54 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
